Stay updated on Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial page
- Check5 days agoChange DetectedMelanoma content and the MedlinePlus Genetics related topics were removed from the page.SummaryDifference0.1%

- Check12 days agoChange DetectedAdded Melanoma topic, MedlinePlus Genetics link, and a new JAMA Netw Open citation related to adjuvant pembrolizumab in melanoma.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA new site revision label, v3.4.2, was added and an older revision (v3.4.1) along with some topic tags (Melanoma, MedlinePlus Genetics, related topics) were removed. These appear to be administrative updates to the page's metadata.SummaryDifference0.2%

- Check34 days agoChange DetectedAdded a site-wide notice about government funding and operations; Melanoma related topics were added, and the page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check41 days agoChange DetectedAdded a glossary toggle and Plain Language Summary, plus IPD sharing information and related links (IPD Sharing Url and IPD Plan Description). Also included Merck-related information sections and downloadable documents (Study Protocol and Statistical Analysis Plan).SummaryDifference100%

- Check48 days agoChange DetectedAdded related topic links for Melanoma and MedlinePlus Genetics on the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial page.